JPRN-UMIN000012161已完成未知
local intraarterial fibrinolysis in central retinal arteryy occlusion - LIF in CRAO
St. Marianna University School of Medicine, Yokohama City Seibu Hospital0 个研究点目标入组 30 人开始时间: 2013年10月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)improvement of visual acuity before treatment 2)the case in which the difficulty is became clear by examination before treatment for the approach to an ophthalmic artery 3)the case in which cerebral hemorrhage is diagnosed by examination before treatment 4)When a systemic bleeding disorder exists within three months 5)When consent acquisition for treatment cannot be carried out 6)The case diagnosed as angitis clinically or on examination 7)When the phenomenon remarkably being difficultty for treatment exists
研究者
相似试验
招募中
不适用
Clinical study of vitreous surgery with direct central retinal artery massage for the treatment of central retinal artery occlusioSurgery - Surgical techniquesEye - Diseases / disorders of the eyecentral retinal artery occlusionACTRN12609001042235Beijing Tongren Eye Center300
进行中（未招募）
1 期
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY(TenCRAOS): A RANDOMIZED CONTROLLED TRIAL OF ACUTE CLOTSOLVING MEDICATION IN CENTRAL RETINALY ARTERY OCCLUSION.Central retinal artery occlusionEUCTR2018-002546-36-NOOslo University Hospital78
进行中（未招募）
1 期
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY(TenCRAOS): A RANDOMIZED CONTROLLED TRIAL OF ACUTE CLOTSOLVING MEDICATION IN CENTRAL RETINALY ARTERY OCCLUSION.Central retinal artery occlusionEUCTR2018-002546-36-LTOslo University Hospital78
进行中（未招募）
1 期
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY(TenCRAOS): A RANDOMIZED CONTROLLED TRIAL OF ACUTE CLOTSOLVING MEDICATION IN CENTRAL RETINALY ARTERY OCCLUSION.Central retinal artery occlusionEUCTR2018-002546-36-FIOslo University Hospital78
招募中
3 期
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY
(TenCRAOS):
A Prospective, randomised-controlled, double-dummy, double-blind phase 3 multi-centre trial of
TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation)Central retinal artery occlusion2024-517606-29-00Oslo University Hospital HF76